Lyon wrote:Hi Harry,HarryZ wrote:When I spoke to him a couple of years ago, he told me that they didn't see that much of an improvement with their patient group.
What do you think he meant by that? Not much of an improvement of symptoms or not much slowing down of progression?
The initial conversation that I had with the neuro was during the trials when of course, being double blinded, nobody knew who was actually getting the drug. The comment I was given at the time was that some patients became worse, some remained the same and others were showing improvement. Unfortunately I can't elaborate on what "showing improvement" or "becoming worse" meant since he wasn't specific.
The second time that I spoke to the neuro was after their trial group had completed the study. Again, he wasn't detailed in his opinion of Tysabri at the time but said that the results he experienced were mixed. I said to him at the time that Biogen had made press releases indicating that Tysabri was far superior than anything out there at the time and that's when he made the comment that Biogen didn't exactly have the best reputation in the medical world for giving totally accurate data in their trials. He went on further to say that Tysabri looked like it would be good for mild case MS....not surprising in that only patients who were I believe 2.0 or lower on the EDSS scale participated in the trials.
So it looks like depending on who you talk to one gets different opinions on Tysabri. Ewizabeth's neuro seemed to experience far better results than what people got here. Kind of sounds like what happens when it comes to MS medications, doesn't it?